Technetium-99m Market Growth Drivers and Forecast by 2031

Historic Data: 2021-2023   |   Base Year: 2024   |   Forecast Period: 2025-2031

Technetium-99m Market Size and Forecasts (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Application Area (Cardiovascular, Bone Scan, Respiratory, Tumor Imaging, and Others), End User (Hospitals, Diagnostic and Imaging Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)

  • Report Date : Aug 2025
  • Report Code : TIPRE00029981
  • Category : Life Sciences
  • Status : Data Released
  • Available Report Formats : pdf-format excel-format
  • No. of Pages : 150

The technetium-99m market size is expected to grow from US$ 4.61 billion in 2024 to US$ 6.29 billion by 2031; it is anticipated to record a CAGR of 3.9% from 2025 to 2031.

Technetium-99m Market Insights and Analyst View:

Technetium-99m is a metastable nuclear isomer of technetium-99, an isotope of technetium. Technetium-99m is among the most commonly used medical radioisotopes in medical diagnostic procedures globally. Key factors driving the market are the high prevalence of chronic diseases and advancements in nuclear imaging techniques. However, the short shelf-life of radiopharmaceuticals hinders the technetium-99m market

Growth Drivers and Restraints:

The high prevalence of chronic diseases such as cardiovascular diseases (CVDs), respiratory diseases, and cancer cases will boost the demand for single-photon emission computed tomography (SPECT) diagnostic procedures, fueling the technetium-99m market growth. According to the Washington State Department of Health, technetium-99m is used in diagnostic procedures related to skeleton and heart muscles. It is also used in medical studies related to the lungs, liver, spleen, bone marrow, kidney, brain, thyroid, gall bladder, salivary glands, heart blood pool, infection, and others. Thus, a high prevalence of chronic diseases will increase the adoption of technetium-99m for diagnosis.

According to the American College of Cardiology Foundation, the CVD-related death counts increased from 12.4 million deaths in 1990 to 19.8 million deaths in 2022. Ischemic heart disease remains the leading cause of global CVD mortality. Similarly, according to the International Agency for Research on Cancer (IARC), the prevalence of cancer cases is high globally. It is estimated that there were 19.3 million cancer cases worldwide in 2020, and the number of cases is expected to reach ~30.2 million cancer cases by 2040. Further, the World Health Organization (WHO) states that more than 1.71 billion people globally suffer from musculoskeletal conditions. An effective medical examination is a must for treating chronic diseases, and some medical imaging procedures also include nuclear substances that are used for diagnosis and examination purposes. Radiopharmaceuticals such as technetium-99m and iodine-123 are used in SPECT, and similarly, fluorine-18 and copper-64 are used in positron emission tomography (PET). Thus, with a surge in the prevalence of chronic diseases, the demand for medical imaging is also increasing the technetium-99m market size.

However, the short shelf-life of radiopharmaceuticals hampers the market growth. The shelf-life of radiopharmaceuticals depends mainly on the radioisotopes' half-life, radiochemical stability, and the concentration of radionuclide impurities in the preparation. Most radiopharmaceutical preparations contain radioisotopes with very short half-lives. For example, technetium-based and SPECT preparations must be used within 6 hours of preparation. The shelf-life of a multidose radiopharmaceutical preparation after aseptic withdrawal of the first dose depends on microbiological considerations. In case of a short half-life of radionuclides, the diagnostic radiopharmaceuticals are usually prepared in the hospital radiopharmacy departments just before the administration to patients. For example, the physical half-life of technetium-99m is 6 hours and does not remain in the body for long. Therefore, short-lived radiopharmaceuticals are becoming a matter of concern in long-term procedures, which is a major factor restraining the technetium-99m market growth.

Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Technetium-99m Market: Strategic Insights

technetium-99m-market
  • Get Top Key Market Trends of this report.
    This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Report Segmentation and Scope:

The technetium-99m market analysis is drawn by considering the following segments: application area and end user. Based on application area, the market is segmented into cardiovascular, bone scan, respiratory, tumor imaging, and others. In terms of end user, the market is categorized into hospitals, diagnostic and imaging centers, and others. The scope of the technetium-99m market report covers North America (the US, Canada, and Mexico), Europe (Germany, France, Italy, the UK, Russia, and the Rest of Europe), Asia Pacific (Australia, China, Japan, India, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Segmental Analysis:

Based on application area, the technetium-99m market is segmented into cardiovascular, bone scan, respiratory, tumor imaging, and others. The cardiovascular segment held the largest technetium-99m market share in 2022. The bone scan segment is anticipated to register the highest CAGR during 2022–2030.

Based on end user, the market is segmented into hospitals, diagnostic and imaging centers, and others. In 2022, the diagnostic and imaging centers segment held the largest technetium-99m market share, and the hospitals segment is anticipated to register the highest CAGR during 2022–2030.

Regional Analysis:

Geographically, the global technetium-99m market is segmented into five key regions: North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

In 2022, North America held the largest global share in the market. The availability of advanced healthcare infrastructure, the presence of major market players, the rising incidence and prevalence of target conditions, and product innovations introduced by key players operating in the region are likely to introduce new technetium-99m market trends in the coming years. According to the International Agency for Research on Cancer (IARC), the number of cancer cases in the US is expected to increase from 2.28 million cases in 2020 to 3.12 million cases in 2040. Therefore, an increase in chronic diseases, including cancer, will fuel the demand for medical imaging, thereby boosting the market growth. Additionally, the Centers for Medicare & Medicaid Services (CMS) in the US has adopted standards associated with human laboratory research under the Clinical Laboratory Improvement Amendments (CLIA), which has favorably improved the technetium-99m market performance.

Industry Developments and Future Opportunities:

A few initiatives taken by key players operating in the global market are listed below:

  • In November 2023, the International Atomic Energy Agency (IAEA) announced a new coordinated research project (CRP) to create a global network of producers and researchers to develop a new generation of Technetium-99m kits and radiopharmaceuticals. The CRP is anticipated to create standard processes and guidelines for the manufacturing, quality control, and preclinical testing of innovative technetium-99m radiopharmaceuticals. The CRP will also concentrate on the most therapeutically relevant supplies in demand and the implementation of innovative radiolabeling strategies.
  • In February 2023, BWXT Medical completed the key Tc-99m generator program milestone with Laurentis. Laurentis Energy Partners and BWXT Medical Ltd. have installed and commissioned an innovative isotope system at Ontario Power Generation's (OPG) Darlington Nuclear Generating Station, enabling them to generate molybdenum-99 (Mo-99) isotopes. Mo-99 is used to generate Technetium-99 metastable (Tc-99m), one of the most often used diagnostic imaging agents in nuclear medicine, which aids in detecting conditions such as cancer and heart disease. Darlington will be the first commercial power reactor to produce Mo-99.
  • In February 2022, Theragnostics announced that the company received the US FDA approval for its radiodiagnostic imaging drug NephroScan (Technetium Tc 99m Succimer injection kit). NephroScan is a proprietary kit for the preparation of technetium Tc 99m succimer injection, which acts as an aid for the diagnosis of renal parenchymal disorders in term neonates and adult patients.
  • In March 2021, NorthStar Medical Radioisotopes LLC and Ion Beam Applications SA (IBA) announced a collaboration to increase the global availability of technetium-99m (Tc-99m), the most widely used medical radioisotope. The agreement allows businesses outside the US to use NorthStar's patented non-uranium-based Mo-99 generated using IBA's accelerators and beamlines. Furthermore, the collaboration builds on an existing agreement under which IBA will supply NorthStar with up to eight Rhodotron TT 300-HE electron beam accelerators. This aids in the production of non-uranium-based Mo-99, allowing NorthStar's FDA-approved and commercially accessible RadioGenix System (technetium Tc 99m generator) to manufacture Tc-99m in the US.

Technetium-99m Market Regional Insights

The regional trends and factors influencing the Technetium-99m Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Technetium-99m Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

technetium-99m-market-global-geography
  • Get the Regional Specific Data for Technetium-99m Market

Technetium-99m Market Report Scope

Report Attribute Details
Market size in 2024 4.61 Billion
Market Size by 2031 6.29 Billion
Global CAGR (2024 - 2031) 3.9%
Historical Data 2021-2023
Forecast period 2025-2031
Segments Covered By Application Area
  • Cardiovascular
  • Bone Scan
  • Respiratory
  • Tumor Imaging
By End User
  • Hospitals
  • Diagnostic and Imaging Centers
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Lantheus Medical Imaging Inc
  • Curium
  • Jubilant Pharma Company
  • NorthStar Medical Radioisotopes LLC
  • Sun Pharmaceutical Industries Inc
  • Advancing Nuclear Medicine
  • NTP Radioisotopes SOC Ltd
  • Northwest Medical Isotopes LLC
  • SHINE Technologies LLC
  • Cardinal Health

  • Technetium-99m Market Players Density: Understanding Its Impact on Business Dynamics

    The Technetium-99m Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

    Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.

    Major Companies operating in the Technetium-99m Market are:

    1. Lantheus Medical Imaging Inc
    2. Curium
    3. Jubilant Pharma Company
    4. NorthStar Medical Radioisotopes LLC
    5. Sun Pharmaceutical Industries Inc
    6. Advancing Nuclear Medicine

    Disclaimer: The companies listed above are not ranked in any particular order.


    technetium-99m-market-cagr

    • Get the Technetium-99m Market top key players overview

    Competitive Landscape and Key Companies:

    Lantheus Medical Imaging Inc, Curium, Jubilant Pharma Company, NorthStar Medical Radioisotopes LLC, Sun Pharmaceutical Industries Inc, Advancing Nuclear Medicine, NTP Radioisotopes SOC Ltd, Northwest Medical Isotopes LLC, SHINE Technologies LLC, and Cardinal Health are among the prominent players profiled in the technetium-99m market report. These companies focus on new technologies, advancements in existing products, and geographic expansions to meet the growing consumer demand worldwide and increase their product range in specialty portfolios.


    Frequently Asked Questions

    What are the growth estimates for the technetium-99m market till 2031?

    The technetium-99m market is expected to be valued at US$ 6.29 billion in 2031.

    Which application area segment dominates the technetium-99m market?

    Based on application area, the technetium-99m market is segmented into cardiovascular, bone scan, respiratory, tumor imaging, and others. The cardiovascular segment held the largest technetium-99m market share in 2022. The bone scan segment is anticipated to register the highest CAGR during 2022–2030.

    Which end user segment dominates the technetium-99m market?

    Based on end user, the market is segmented into hospitals, diagnostic and imaging centers, and others. In 2022, the diagnostic and imaging centers segment held the largest technetium-99m market share, and the hospitals segment is anticipated to register the highest CAGR during 2022–2030.

    What factors drive the technetium-99m market?

    Key factors driving the market are the high prevalence of chronic diseases and advancements in nuclear imaging techniques.

    What was the estimated technetium-99m market size in 2024?

    The technetium-99m market was valued at US$ 4.61 billion in 2022.

    What is technetium-99m?

    Technetium-99m is a metastable nuclear isomer of technetium-99, an isotope of technetium. Technetium-99m is among the most commonly used medical radioisotopes in medical diagnostic procedures globally.

    Who are the major players in the technetium-99m market?

    The technetium-99m market majorly consists of the players, including Lantheus Medical Imaging Inc, Curium, Jubilant Pharma Company, NorthStar Medical Radioisotopes LLC, Sun Pharmaceutical Industries Inc, Advancing Nuclear Medicine, NTP Radioisotopes SOC Ltd, Northwest Medical Isotopes LLC, SHINE Technologies LLC, and Cardinal Health.

    Mrinal Kerhalkar
    Mrinal Kerhalkar
    Manager,
    Market Research & Consulting

    Mrinal is a seasoned research analyst with over 8 years of experience in Life Sciences Market Intelligence and Consulting. With a strategic mindset and unwavering commitment to excellence, she has built deep expertise in pharmaceutical forecasting, market opportunity assessment, and developing industry benchmarks. Her work is anchored in delivering actionable insights that empower clients to make informed strategic decisions.

    Mrinal’s core strength lies in translating complex quantitative datasets into meaningful business intelligence. Her analytical acumen is instrumental in shaping go-to-market (GTM) strategies and uncovering growth opportunities across the pharmaceutical and medical device sectors. As a trusted consultant, she consistently focuses on streamlining workflow processes and establishing best practices, thereby driving innovation and operational efficiency for her clients.

    • Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
    • PEST and SWOT Analysis
    • Market Size Value / Volume - Global, Regional, Country
    • Industry and Competitive Landscape
    • Excel Dataset

    Testimonials

    user

    I wish to appreciate your support and the professionalism you displayed in the course of attending to my request for information regarding to infectious disease IVD market in Nigeria. I appreciate your patience, your guidance, and the fact that you were willing to offer a discount, which eventually made it possible for us to close a deal. I look forward to engaging The Insight Partners in the future, all thanks to the impression you have created in me as a result of this first encounter.

    DR CHIJIOKE ONYIA, MANAGING DIRECTOR, PineCrest Healthcare Ltd.
    user

    The Insight Partners delivered insightful, well-structured market research with strong domain expertise. Their team was professional and responsive throughout. The user-friendly website made accessing industry reports seamless. We highly recommend them for reliable, high-quality research services

    Yukihiko Adachi CEO, Deep Blue, LLC.

    Reason to Buy

    • Informed Decision-Making
    • Understanding Market Dynamics
    • Competitive Analysis
    • Customer Insights
    • Market Forecasts
    • Risk Mitigation
    • Strategic Planning
    • Investment Justification
    • Identifying Emerging Markets
    • Enhancing Marketing Strategies
    • Boosting Operational Efficiency
    • Tracking Industry Innovations
    • Aligning with Regulatory Trends
    Your Key Concerns Addressed - Question & Answer
    Can I view a sample of the report before purchasing?

    Yes! We provide a free sample of the report, which includes Report Scope (Table of Contents), report structure, and selected insights to help you assess the value of the full report. Please click on the "Download Sample" button or contact us to receive your copy.

    Is analyst support included with the purchase?

    Absolutely — analyst assistance is part of the package. You can connect with our analyst post-purchase to clarify report insights, methodology or discuss how the findings apply to your business needs.

    What are the next steps once I place an order?

    Once your order is successfully placed, you will receive a confirmation email along with your invoice.

    • For published reports: You’ll receive access to the report within 4–6 working hours via a secured email sent to your email.
    • For upcoming reports: Your order will be recorded as a pre-booking. Our team will share the estimated release date and keep you informed of any updates. As soon as the report is published, it will be delivered to your registered email.

    Can the report be tailored to suit my specific needs?

    We offer customization options to align the report with your specific objectives. Whether you need deeper insights into a particular region, industry segment, competitor analysis, or data cut, our research team can tailor the report accordingly. Please share your requirements with us, and we’ll be happy to provide a customized proposal or scope.

    In what format is the report delivered?

    The report is available in either PDF format or as an Excel dataset, depending on the license you choose.

    The PDF version provides the full analysis and visuals in a ready-to-read format. The Excel dataset includes all underlying data tables for easy manipulation and further analysis.
    Please review the license options at checkout or contact us to confirm which formats are included with your purchase.

    How secure is the payment process on your platform?

    Our payment process is fully secure and PCI-DSS compliant.

    We use trusted and encrypted payment gateways to ensure that all transactions are protected with industry-standard SSL encryption. Your payment details are never stored on our servers and are handled securely by certified third-party processors.
    You can make your purchase with confidence, knowing your personal and financial information is safe with us.

    Do you provide special pricing for buying multiple reports?

    Yes, we do offer special pricing for bulk purchases.
    If you're interested in purchasing multiple reports, we’re happy to provide a customized bundle offer or volume-based discount tailored to your needs. Please contact our sales team with the list of reports you’re considering, and we’ll share a personalized quote.

    Can I connect with your team to discuss the report before buying?

    Yes, absolutely.
    Our team is available to help you make an informed decision. Whether you have questions about the report’s scope, methodology, customization options, or which license suits you best, we’re here to assist. Please reach out to us at sales@theinsightpartners.com, and one of our representatives will get in touch promptly.

    Will I get a billing invoice upon purchase?

    Yes, a billing invoice will be automatically generated and sent to your registered email upon successful completion of your purchase.
    If you need the invoice in a specific format or require additional details (such as company name, GST, or VAT information), feel free to contact us, and we’ll be happy to assist.

    Is there support available if I can’t access my report?

    Yes, certainly.
    If you encounter any difficulties accessing or receiving your report, our support team is ready to assist you. Simply reach out to us via email or live chat with your order information, and we’ll ensure the issue is resolved quickly so you can access your report without interruption.

    Our Clients

    The List of Companies - Technetium-99m Market

    1. Lantheus Medical Imaging Inc
    2. Curium
    3. Jubilant Pharma Company
    4. NorthStar Medical Radioisotopes LLC
    5. Sun Pharmaceutical Industries Inc
    6. Advancing Nuclear Medicine
    7. NTP Radioisotopes SOC Ltd
    8. Northwest Medical Isotopes LLC
    9. SHINE Technologies LLC
    10. Cardinal Health
    Sales Assistance
    US: +1-646-491-9876
    UK: +44-20-8125-4005
    Email: sales@theinsightpartners.com
    Chat with us
    DUNS Logo
    87-673-9708
    ISO Certified Logo
    ISO 9001:2015
    ISO Certified Logo